| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD52 |
| Uniprot No | P31358 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-36aa |
| 氨基酸序列 | GQNDTSQTSSPSLEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDG SFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKHHHHH H |
| 预测分子量 | 28 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD52重组蛋白的模拟参考文献示例(实际文献需通过学术数据库验证)：
---
1. **文献名称**: *Structural and functional characterization of recombinant human CD52 antigen*
**作者**: Smith A, et al.
**摘要**: 本研究通过基因工程技术表达并纯化了重组人CD52蛋白，解析了其糖基化修饰特征及细胞表面定位机制，揭示了CD52在免疫细胞信号调控中的作用。
---
2. **文献名称**: *CD52 as a therapeutic target in autoimmune diseases: Insights from recombinant protein models*
**作者**: Brown L, et al.
**摘要**: 通过重组CD52蛋白的体外实验，验证了其与抗CD52单克隆抗体(如阿仑单抗)的结合活性，探讨了靶向CD52治疗多发性硬化症等自身免疫疾病的分子机制。
---
3. **文献名称**: *Recombinant CD52 fusion protein enhances T-cell depletion in transplantation*
**作者**: Zhang Y, et al.
**摘要**: 构建了CD52-Fc融合蛋白，证明其可增强补体依赖性细胞毒性，为优化器官移植中的免疫抑制方案提供了新策略。
---
4. **文献名称**: *Comparative analysis of CD52 isoforms across species using recombinant expression*
**作者**: Müller R, et al.
**摘要**: 通过重组表达不同物种(人、小鼠、灵长类)的CD52蛋白，比较了其结构保守性和功能差异，为跨物种免疫治疗研究提供基础数据。
---
**注意**：以上为模拟生成的文献条目，实际文献请通过 **PubMed/Google Scholar** 检索关键词如 *"CD52 recombinant protein"* 或 *"CD52 monoclonal antibody"* 获取。经典文献可参考阿仑单抗(Campath-1H)相关研究(如2001年*New England Journal of Medicine*发表的临床试验)。
CD52 recombinant protein is derived from the CD52 antigen, a small, glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein encoded by the *CD52* gene in humans. First identified in the 1980s, CD52 is highly expressed on immune cells, including T and B lymphocytes, monocytes, and macrophages, with particularly dense presence on mature spermatozoa. Its structure comprises a short 12-amino acid peptide core (≈25–29 kDa when glycosylated) linked to a complex carbohydrate moiety, contributing to its stability and functional diversity. Despite its simple peptide backbone, CD52’s biological significance lies in its role as an immunomodulatory molecule.
CD52 interacts with inhibitory receptors like Siglec-10 on neighboring cells, dampening T-cell activation and promoting immune tolerance. This mechanism is exploited therapeutically; the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) targets CD52 to deplete lymphocytes in conditions such as chronic lymphocytic leukemia and multiple sclerosis. However, CD52’s exact physiological functions remain partially enigmatic, with studies suggesting roles in sperm maturation, immune regulation, and inflammatory responses.
Recombinant CD52 protein is engineered using expression systems like mammalian CHO or bacterial cells, enabling scalable production for research and drug development. Its recombinant form retains key epitopes for antibody binding studies but may lack native glycosylation patterns unless expressed in mammalian hosts. Researchers utilize this protein to investigate CD52-mediated signaling pathways, develop diagnostic tools, or optimize therapeutic antibodies. Challenges include preserving post-translational modifications critical for functional studies. Current interest focuses on CD52’s dual role in immune suppression and cancer evasion, positioning it as a potential target for immunotherapy. Ongoing studies aim to unravel its interactions with the tumor microenvironment and its utility in autoimmune or transplantation therapies.
×
